Edaravone

BreastfeedingPediatric
  • TRADE NAME: Radicava (Mitsubishi Tanabe Pharma)
  • INDICATIONS: Amyotrophic lateral sclerosis
  • CLASS: Antioxidant
  • HALF-LIFE: 4–6 hours

FDA APPROVAL DATE: 05/05/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
May cause fetal toxicity based on findings in animal studies

Radicava contains sodium bisulfite which may cause allergic type reactions.

Our database has 37 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 09/24/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top